NexGel (NXGL) terminated CEO Adam R. Levy without cause effective August 21, 2026, and he also resigned from the board and every other role he held at the company and its subsidiaries. The board tapped Brian Kieser — a director since May 2026 — as interim CEO; he's the founder and CEO of San Antonio-based Fountainhead Lifesciences and also runs Sequence LifeScience, a company NexGel already has a strategic partnership with. A few big details are still open: Levy's separation agreement is still being negotiated, and Kieser's interim pay hasn't been set yet, so amended 8-Ks will follow.
View Full Filing (SEC EDGAR)